Global Aromatase Deficiency Market – Industry Trends and Forecast to 2029

Market Analysis and Size                              

Aromatase insufficiency is characterized by a hormonal imbalance, which disrupts sexual development and maturation due to low estrogen levels and high testosterone levels. Babies who are genetically female (have two X chromosomes) frequently have genitals that are not unmistakably female or male (known as ambiguous genitalia). Their reproductive organs are usually normal, however patients may develop ovarian cysts as children, and breast growth and periods may be affected during their teenage years. Males with tiny or undescended testes are rarely identified until later in life. Males may also suffer from a lack of sexual desire, inadequate sperm production, infertility, or bone weakness.

Data Bridge Market Research analyses that the aromatase deficiency market was valued at USD 90.45 million in 2021 and is expected to reach USD 109.35 million by 2029, registering a CAGR of 2.40% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

 Aromatase deficiency is an uncommon condition that affects the synthesis of estradiol, causing hirsutism in pregnant women, pseudohermaphroditism and virilization in women, and tall height, osteoporosis, and obesity in men. Female patients may be candidates for surgical genitalia modification depending on the degree of ambiguity, and ovarian cysts must be monitored. After puberty, daily estrogen treatment (0.625 mg/twice weekly increasing to daily) is required, which can be augmented with progesterone-like hormone and monthly gonadotrophin-releasing hormone antagonist therapies. Adult men should begin treatment as soon as possible after being diagnosed, with daily transdermal delivery of up to 50 g of estradiol for 6-9 months to complete skeletal development. Estradiol replacement may be lowered to 25 g per day after epiphyseal closure. Calcium, vitamin D, and physical activity should be included to a low-calorie diet. Symptomatic treatment is required for dyslipidemia, insulin resistance and glucose intolerance.

Aromatase Deficiency Market Dynamics

Drivers

• Rise in the number of cases of aromatase deficiency

The surging number of cases of aromatase deficiency is a major factor driving the market's growth rate during the forecast period of 2022-2029. Aromatase deficiency is a sexual development condition characterized by low estrogen levels and high testosterone leels. Because of excessive growth of long bones in the arms and legs, affected people are abnormally tall. The aberrant bone growth causes slower mineralization and bone thinning, which can result in bone fractures with little impact.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of aromatase deficiency market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising government initiatives to spread awareness and sedentary lifestyle of people will result in the expansion of aromatase deficiency market. Along with this, favourable reimbursement policies will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the aromatase deficiency market growth.

Moreover, the market's growth is fueled by rising technological advancement in diagnostic methods and emerging new markets. These factors will provide beneficial opportunities for the aromatase deficiency market growth.

Restraints/Challenges

On the other hand, high cost associated with the treatment as well as diagnosis will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the aromatase deficiency market. Additionally, lack of awareness among people and unfavourable healthcare policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This aromatase deficiency market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the aromatase deficiency market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Aromatase deficiency market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global Aromatase Deficiency Market Scope

The aromatase deficiency market is segmented on the basis of diagnosis, treatment, route of administration, age of onset, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Physical Examination
• Gene Sequencing
• Genetic testing
• Others

Treatment

• Surgery
• Estrogen Replacement
• Others

Age of Onset

• Pediatrics
• Adults
• Geriatrics

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Aromatase Deficiency Market Regional Analysis/Insights

The aromatase deficiency market is analysed and market size insights and trends are provided by country, diagnosis, treatment, route of administration, age of onset, end-users and distribution channel as referenced above.

The countries covered in the aromatase deficiency market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the aromatase deficiency market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing prevalence of aromatase deficiency and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, growing presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to development of healthcare infrastructure in this region. Also, rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Aromatase Deficiency Market Share Analysis

The aromatase deficiency market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to aromatase deficiency market.

Some of the major players operating in the aromatase deficiency market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Eli Lilly and Company (US)
• Merck & Co., Inc. (US)
• Allergan (Ireland)
• Abbott (US)
• Merck KGaA (Germany)
• Novo Nordisk A/S (Denmark)
• Genentech Inc. (US)
• Amgen Inc. (US)
• Endo International plc (Ireland)
• Hisamitsu Pharmaceutical Co.,Inc. (Japan)

SKU-68374